ABT-751 + carboplatin

ABT-751 + carboplatin is a combination of two investigational anticancer agents. ABT‑751 is an orally bioavailable small molecule sulphonamide that binds to the colchicine-binding site on β-tubulin, inhibiting microtubule polymerization and thereby preventing tumor cell replication. It also exhibits antivascular properties by disrupting tumor blood vessels and causing endothelial cell retraction[2][6]. Carboplatin is a platinum-containing alkylating agent that interferes with DNA replication and transcription, leading to apoptosis in rapidly dividing cells[8]. The combination has been studied primarily in advanced non-small cell lung cancer (NSCLC), where it demonstrated modest clinical activity and acceptable toxicity profiles in early-phase trials[1][4]. ABT‑751 was developed by Abbott Laboratories (now AbbVie), while carboplatin is marketed under several brand names including Paraplatin.

Other names

N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamideN-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamideN-[2-(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide